Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384544 | 1.00 | KMT2A (0.55) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL27792518 | 0.88 | KMT2A (0.57) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL13313529 | 0.83 | SMN1; SMN2 (0.50) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL15084622 | 0.83 | KMT2A (0.55) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL15084647 | 0.83 | ALDH1A1 (0.56) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL10732850 | 0.83 | ALDH1A1 (0.56) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL10732842 | 0.83 | ALDH1A1 (0.56) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL23839926 | 0.83 | MAPT (0.51) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL2383745 | 0.83 | CYP19A1 (0.48) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL2383748 | 0.83 | CYP19A1 (0.48) | KMT2AMAPTMEN1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012991-B2 | 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate | SANOFI-AVENTIS (FR) | 2011-09-06 | — | — | US | disclosed |
| EP-1175407-B1 | PESTICIDAL PYRIMIDINE-DERIVATIVES | NOVARTIS AG (CH) | 2009-12-09 | — | — | EP | disclosed |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| US-7390818-B2 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-06-24 | — | — | US | disclosed |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | disclosed |
| US-6686469-B2 | TREATMENT FOR PLANT PROPAGATION MATERIAL FOR PARASITICIDES | NOVARTIS ANIMAL HEALTH US, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030004347-A1 | Pesticidal pyrimidine-derivatives | NOVARTIS ANIMAL HEALTH US, INC. | 2003-01-02 | — | — | US | disclosed |
| EP-1175407-A1 | PESTICIDAL PYRIMIDINE-DERIVATIVES | Syngenta Participations AG (CH) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066565-A1 | PESTICIDAL PYRIMIDINE-DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | PNPO, PDXK, PLPBP | KMT2A 3749/4885MAPT 1995/4885MEN1 1598/4885 |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | PNPO, PLPBP, DPYD | KMT2A 4272/4885MAPT 2131/4885MEN1 1837/4885 |
| US-20030004347-A1 | Pesticidal pyrimidine-derivatives | CTRC, HCN1, DDT | KMT2A 2493/4885MAPT 4660/4885MEN1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.